官方服务：
资源简介：
Create a recominant DNA act as a aptamer using in cancer treatment.
应用场景：
创建时间：
2019-04-05
相关数据集
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
Aim: This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors. Methods: Patients received MEDI5083 (3–7.5 m
DataCite Commons2024-10-03 更新110
TIVAD: 7 year follow up
A total of 204 adult cancer patients who underwent TIVAD placement via subclavian vein catheter insertion using the Seldinger technique between January 2010 and December 2011 at a tertiary care center
DataCite Commons2025-06-01 更新90
Supplementary Material for: Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
Introduction: In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/pacl
DataCite Commons2025-05-01 更新80
Supplementary Material:Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study
Supplementary Materials for the manuscript: Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-ins
Mendeley Data2024-01-31 更新90
Recent advances in nano-molybdenum oxide for photothermal cancer therapy
Cancer remains a significant global health challenge, driving the search for innovative treatments. Photothermal therapy (PTT) has emerged as a promising approach, using photothermal agents to convert
DataCite Commons2025-04-08 更新80
